DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Information source: Biogen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Non-Small Cell Lung Cancer

Intervention: BIIB022 With Paclitaxel and Carboplatin (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Biogen

Summary

The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Clinical Details

Official title: A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age >/= 18 years old

- Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer

- ECOG Performance Status 0 or 1

Exclusion Criteria:

- History of another primary cancer within 3 years

- Any prior or concurrent investigational or standard therapy for treatment of NSCLC

- Prior anti-IGF-1R therapy

- Unstable diabetes

Locations and Contacts

Resesarch Site, Los Angeles, California, United States

Resesarch Site, San Diego, California, United States

Resesarch Site, Denver, Colorado, United States

Additional Information

Starting date: October 2009
Last updated: September 12, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017